[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371803-105":59,"doc-detail-371803-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","restoring-tamoxifen-sensitivity-in-breast-cancer-the-role-of-lncrna-malat1-and-nanocurcumin-as-modulators-of-drug-resistance","Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance","","Tamoxifen resistance remains a major barrier to durable outcomes in estrogen receptor–positive breast cancer, where long noncoding RNAs (lncRNAs) including MALAT1 are implicated in endocrine resistance. This study evaluates whether NanoCurcumin, a bioavailable curcumin formulation, combined with tamoxifen modulates lncRNA expression and resistance mechanisms. Plasma qRT-PCR in luminal patients and qRT-PCR in MCF7/MCF10 and tamoxifen-resistant models demonstrate NanoCurcumin-driven MALAT1 downregulation and reduced resistance, supporting a potential epigenetic strategy for enhancing endocrine therapy efficacy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/restoring-tamoxifen-sensitivity-in-breast-cancer-the-role-of-lncrna-malat1-and-nanocurcumin-as-modulators-of-drug-resistance/371803/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/restoring-tamoxifen-sensitivity-in-breast-cancer-the-role-of-lncrna-malat1-and-nanocurcumin-as-modulators-of-drug-resistance/371803.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in ER+ breast cancer?","Question",{"text":113,"@type":114},"The study addresses tamoxifen resistance, which commonly develops after long-term hormone therapy and contributes to recurrence and poor prognosis in estrogen receptor–positive breast cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was NanoCurcumin tested with tamoxifen?",{"text":118,"@type":114},"Plasma levels of selected lncRNAs were measured by qRT-PCR in luminal breast cancer patients treated with tamoxifen alone or combined with NanoCurcumin oral soft gels for six months, and parallel qRT-PCR experiments were performed in MCF7, MCF10, and tamoxifen-resistant MCF7 cells.",{"name":120,"@type":111,"acceptedAnswer":121},"What is the key finding related to MALAT1?",{"text":122,"@type":114},"NanoCurcumin significantly reduced MALAT1 expression in clinical samples and reversed MALAT1 elevation in vitro, sustaining low MALAT1 levels and mitigating tamoxifen resistance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},371803,1790216560,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Wiley  \nBioMed Research International  \nVolume 2025, Article ID 5824748, 11 pages [https://doi.org/10.1155/bmri/5824748](https://doi.org/10.1155/bmri/5824748)  \nResearch Article  \nRestoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance  \nFatemeh Nasiri Kenari , 1 Masoumeh Saberian ,2 Matthew Abikenari ,3 Safa Najafi  4  \n,  \nand Majid Sadeghizadeh 1  \n1Department of Molecular Genetics, Faculty of Biological Science, Tarbiat Modares University, Tehran, Iran  \n2Department of Hematology and Oncology, Valiasr Hospital, Tehran, Iran  \n3Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA  \n4Department of Oncology, Motamed Cancer Institute, Tehran, Iran  \nCorrespondence should be addressed to Majid Sadeghizadeh; [sadeghma@modares.ac.ir](sadeghma@modares.ac.ir)  \nReceived 13 March 2025; Revised 16 July 2025; Accepted 11 August 2025  \nAcademic Editor: Baisakhi Banerjee  \nCopyright © 2025 Fatemeh Nasiri Kenari et al. BioMed Research International published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nBackground: Tamoxifen resistance remains a major clinical challenge in estrogen receptor–positive (ER+) breast cancer, contributing to recurrence and poor prognosis. Long noncoding RNAs (lncRNAs), including MALAT1, UCA1, CYTOR, GAS5, and HOTAIR, have emerged as key regulators of endocrine resistance. Curcumin, a polyphenol with anticancer properties, modulates lncRNA expression, and its bioavailable formulation, NanoCurcumin, enhances therapeutic eﬃcacy. This study evaluates the eﬀects of NanoCurcumin in combination with tamoxifen on lncRNA expression and resistance mechanisms in ER+ breast cancer.  \nMethods: Plasma levels of the selected lncRNAs were assessed via qRT-PCR in luminal breast cancer patients receiving tamoxifen alone or in combination with NanoCurcumin oral soft gels for 6 months. Bioinformatics analysis of MALAT1 expression was performed using the GEO database. In vitro, MALAT1 expression was evaluated in breast cancer (MCF7) and normal breast (MCF10) cell lines via qRT-PCR. Tamoxifen-resistant MCF7 cells were generated through prolonged treatment, and the eﬀectsof NanoCurcumin on MALAT1 expression were analyzed over 4 months.  \nResults: In clinical samples, NanoCurcumin signiﬁcantly reduced MALAT1 expression (p =0  02) and trended toward decreased UCA1, CYTOR, and HOTAIR while increasing GAS5 expression. Bioinformatics analysis conﬁrmed MALAT1 upregulation in tamoxifen-resistant cell lines. In vitro, MALAT1 was signiﬁcantly elevated in MCF7 cells compared to MCF10 and increased over time with tamoxifen treatment alone. NanoCurcumin reversed this trend, sustaining low MALAT1 levels and mitigating resistance.  \nConclusion: Our ﬁndings suggest that NanoCurcumin mitigates tamoxifen resistance by downregulating MALAT1, oﬀering a novel epigenetic strategy to enhance endocrine therapy eﬃcacy. Further studies should explore lncRNA-targeted interventions to improve treatment outcomes in ER+ breast cancer.  \nKeywords: breast cancer; lncRNA MALAT1; NanoCurcumin; plasma biomarker; tamoxifen resistance  \n1. Introduction  \nBreast cancer is a heterogeneous and multifactorial disease, resulting from the accumulation of genetic and epigenetic changes that transform normal cells into cancerous ones [1] . Approximately 70% of breast cancer patients have  \ntumors with high levels of estrogen receptor alpha (ERα), which is targeted during hormone therapy. ERα promotes tumorigenesis and induces cell proliferation. Tamoxifen, a highly eﬀective antiestrogen drug, is widely used in breast cancer patients with ERα-positive status. It competitively blocks ER activation. Unfortunately, the eﬀectiveness of  \n2 BioMed Research International  \nhormone therapy is o","cbCaiq2VMr9EicfZ","https://ap.wps.com/l/cbCaiq2VMr9EicfZ","pdf",942537,11,"English","# Introduction\n## Tamoxifen resistance and lncRNAs\n## Curcumin and NanoCurcumin rationale\n# Methods\n## qRT-PCR assessment and patient treatment\n## Bioinformatics analysis\n## Cell line and in vitro validation\n# Results\n## Clinical lncRNA expression changes\n## Cell line validation and resistance reversal\n# Conclusion","[{\"question\":\"What problem does the study address in ER+ breast cancer?\",\"answer\":\"The study addresses tamoxifen resistance, which commonly develops after long-term hormone therapy and contributes to recurrence and poor prognosis in estrogen receptor–positive breast cancer.\"},{\"question\":\"How was NanoCurcumin tested with tamoxifen?\",\"answer\":\"Plasma levels of selected lncRNAs were measured by qRT-PCR in luminal breast cancer patients treated with tamoxifen alone or combined with NanoCurcumin oral soft gels for six months, and parallel qRT-PCR experiments were performed in MCF7, MCF10, and tamoxifen-resistant MCF7 cells.\"},{\"question\":\"What is the key finding related to MALAT1?\",\"answer\":\"NanoCurcumin significantly reduced MALAT1 expression in clinical samples and reversed MALAT1 elevation in vitro, sustaining low MALAT1 levels and mitigating tamoxifen resistance.\"}]","Restoring Tamoxifen Sensitivity in Breast Cancer: The Role of lncRNA MALAT1 and NanoCurcumin as Modulators of Drug Resistance | PDF",1790192902,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b3685d4ebc17ea82b9914e66f12565c.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab13aeee296c923f2b4939119536f0d8.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4e3f40763475ec211664aa93fede27d.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6efe75f97adbc09b06c469ae4017bab9.webp",980,1306]